Stock News

Old National Bancorp Has Upped Gilead Sciences (GILD) Stake; Scopus Asset Management LP Decreased Eastman Chem Co (EMN) Holding By $12.15 Million

Scopus Asset Management Lp decreased Eastman Chem Co (EMN) stake by 77.14% reported in 2017Q3 SEC filing. Scopus Asset Management Lp sold 135,000 shares as Eastman Chem Co (EMN)’s stock declined 2.09%. The Scopus Asset Management Lp holds 40,000 shares with $3.62M value, down from 175,000 last quarter. Eastman Chem Co now has $14.79 billion valuation. The stock increased 1.90% or $1.93 during the last trading session, reaching $103.44. About 917,777 shares traded. Eastman Chemical Company (NYSE:EMN) has risen 7.60% since February 25, 2017 and is uptrending. It has underperformed by 9.10% the S&P500.

Old National Bancorp increased Gilead Sciences Inc (GILD) stake by 16.57% reported in 2017Q3 SEC filing. Old National Bancorp acquired 4,561 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Old National Bancorp holds 32,092 shares with $2.60 million value, up from 27,531 last quarter. Gilead Sciences Inc now has $105.69 billion valuation. The stock increased 1.90% or $1.51 during the last trading session, reaching $80.91. About 5.63M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 25, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 125 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Thursday, July 27 with “Hold”. Oppenheimer maintained it with “Outperform” rating and $120 target in Wednesday, February 3 report. On Wednesday, November 2 the stock rating was upgraded by BMO Capital Markets to “Outperform”. The firm has “Hold” rating given on Wednesday, August 31 by Jefferies. The firm has “Buy” rating given on Wednesday, November 8 by Mizuho. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, June 14 by William Blair. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 25 report. Needham maintained it with “Buy” rating and $125 target in Wednesday, July 29 report. The firm has “Hold” rating by Oppenheimer given on Wednesday, October 4. The firm has “Buy” rating by Robert W. Baird given on Friday, September 15.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. North Point Managers Oh stated it has 202,405 shares or 2.77% of all its holdings. Logan Capital Incorporated holds 0.02% or 4,120 shares. Moreover, Anderson Hoagland And has 1.58% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Wellington Mngmt Gru Limited Liability Partnership holds 0.03% or 1.54 million shares. Moreover, Rowland Co Inv Counsel Adv has 0.06% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Liberty Capital Management reported 2,540 shares. Lehman Fin Resource Incorporated has invested 1.56% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). 5,014 were accumulated by Bar Harbor Trust. Pggm Invests has 1.93 million shares. Nexus has 258,416 shares for 3.27% of their portfolio. The Illinois-based Arete Wealth Advsrs Limited Co has invested 0.47% in Gilead Sciences, Inc. (NASDAQ:GILD). Aldebaran Fin Incorporated invested in 0.96% or 17,255 shares. Provise Grp Ltd holds 6,268 shares. Moreover, Van Hulzen Asset Ltd Com has 0.2% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Cadence Cap Mgmt Limited Liability Company, Massachusetts-based fund reported 168,324 shares.

Since August 30, 2017, it had 0 buys, and 15 sales for $56.94 million activity. 51,820 shares valued at $4.40 million were sold by Washington Robin L on Thursday, September 7. Another trade for 50,000 shares valued at $3.95M was sold by Alton Gregg H. 50,000 shares were sold by MARTIN JOHN C, worth $4.18M on Thursday, February 1. 100,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $8.02 million were sold by Meyers James R. Another trade for 60,000 shares valued at $4.68M was sold by WILSON GAYLE E.

Old National Bancorp decreased Medtronic Plc (NYSE:MDT) stake by 4,458 shares to 161,764 valued at $12.58 million in 2017Q3. It also reduced Edwards Lifesciences Corp (NYSE:EW) stake by 7,212 shares and now owns 100,310 shares. Chevron Corp New (NYSE:CVX) was reduced too.

Investors sentiment increased to 1.18 in 2017 Q3. Its up 0.04, from 1.14 in 2017Q2. It is positive, as 32 investors sold EMN shares while 175 reduced holdings. 67 funds opened positions while 178 raised stakes. 115.86 million shares or 0.58% less from 116.54 million shares in 2017Q2 were reported. Nomura Hldg owns 0% invested in Eastman Chemical Company (NYSE:EMN) for 7,339 shares. Argyle Capital Mgmt holds 0.12% of its portfolio in Eastman Chemical Company (NYSE:EMN) for 3,400 shares. Lord Abbett & Co Ltd Liability Co has 1.13M shares for 0.3% of their portfolio. Meiji Yasuda Asset Mngmt holds 0.09% of its portfolio in Eastman Chemical Company (NYSE:EMN) for 9,715 shares. The New York-based D E Shaw And Inc has invested 0.01% in Eastman Chemical Company (NYSE:EMN). Stephens Ar owns 17,707 shares. Ftb Advsr holds 0.01% or 1,343 shares. Cubist Systematic Strategies Ltd Limited Liability Company owns 12,064 shares or 0.06% of their US portfolio. Natixis has 3,716 shares for 0% of their portfolio. State Bank Of America De, a North Carolina-based fund reported 1.67 million shares. J Goldman And Co Ltd Partnership has 10,500 shares. Advisor Ltd Liability Corp invested in 0.08% or 4,723 shares. Hanson Mcclain owns 20 shares for 0% of their portfolio. Nuveen Asset Mngmt Limited Liability holds 212,776 shares or 0.13% of its portfolio. Shell Asset Mngmt has invested 0.05% in Eastman Chemical Company (NYSE:EMN).

Since October 31, 2017, it had 0 insider purchases, and 4 sales for $1.63 million activity. On Tuesday, October 31 the insider Stuckey Perry sold $479,024. DEMERITT STEPHEN R had sold 4,000 shares worth $399,360. WARMACK DAMON CARY also sold $435,516 worth of Eastman Chemical Company (NYSE:EMN) on Wednesday, February 7. BOLDEA LUCIAN also sold $315,875 worth of Eastman Chemical Company (NYSE:EMN) on Friday, February 9.

Analysts await Eastman Chemical Company (NYSE:EMN) to report earnings on April, 26. They expect $2.10 earnings per share, up 14.75% or $0.27 from last year’s $1.83 per share. EMN’s profit will be $300.30M for 12.31 P/E if the $2.10 EPS becomes a reality. After $1.62 actual earnings per share reported by Eastman Chemical Company for the previous quarter, Wall Street now forecasts 29.63% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *